Kids and covid, vs. vaccine. Variants and your immune system.

Panelists included Dr. Pierre Kory, Dr. Ryan Cole, Dr. Brian Tyson, Dr. Richard Urso, Dr. Robert Malone, Dr. Heather Gessling, Dr. Brian McDonald, and Dr. John Littell. Moderated by Rob Nelson (ABC, UPN, Fox).

In San Juan, Puerto Rico, a panel of doctors and scientists convened in an open forum about effective early treatment and evaluated the current one-size-fits-all approach to the treatment of Covid.


This is an emergency of under-treatment.

Treat early. Prevention, treatment and early outpatient treatment.

I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19

Below you can download the I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19 with guidance on the timing and doses of each component medication. Further below please find more information on the I-MASK+ Protocol.

The I-MASK+ Protocol complements our MATH+ Hospital Treatment Protocol for COVID-1 from March 2020, which is intended for hospitalized patients. Both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles. In October 2020, we added ivermectin as a core medication in the prevention and treatment of COVID-19.

The protocol document is available in several languages (see below) – more translations are available here. This is not a medical advice, but a recommendation – please consult your doctor, share the information on this website with her/him, and listen. Please review our Disclaimers!

Please check this page regularly for updates – new medications may be added and/or dose changes to existing medications may be made as further scientific studies emerge.

Current I-MASK+ protocol: version 17, updated on September 24, 2021 (English version, translation updates follow).

Prevention & early outpatient treat­ment for COVID-19

Profilaxis y tratamiento am­bu­la­to­rio temprano para COVID-19 

Profilaxia e trata­men­to am­bu­la­to­rial precoce para COVID-19

Prophy­laxie et traite­­ment am­bu­la­­toire précoce COVID‑19

Profilassi e tratta­­men­to am­bu­la­to­rio pre­coce per COVID-19

Prophylaxe & frühe ambu­lante Be­hand­lung von COVID-19

For more translations please go to Translations of Selected Files.

переводы · Traducciones · الترجمات · Çeviriler · Traduções · ਅਨੁਵਾਦ · Traduzioni · 翻訳
Tafsiri · Übersetzungen · Översättningar · अनुवाद · Traductions · மொழிபெயர்ப்புகள்
অনুবাদ · Vertalingen · Μεταφράσεις · Tłumaczenia · भाषांतर · Preklady · ترجمہ · అనువాదాలు

About the I-MASK+ Protocol for COVID-19

In October 2020, the FLCCC Alliance developed a preventive and early outpatient combination treatment protocol for COVID-19 called I-MASK+. It’s centered around ivermectin, a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and has won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical discovery of a rapidly growing published medical evidence base, demonstrating ivermectin’s unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19. Ivermectin is not yet FDA-approved for the treatment of COVID-19, but on Jan 14, 2021, the NIH changed their recommendation for the use of ivermectin in COVID-19 from “against” to “neutral”. (see our  press release).

Our life-saving MATH+ Hospital Treatment Protocol for COVID-19 (available in several languages), created in March 2020, is intended for hospitalized patients. The recently developed I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19 (this page) is designed for use as a prevention and in early outpatient treatment, for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved (except ivermectin), inexpensive, readily available and have been used for decades with well-established safety profiles.

Please download and share our I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19. (It is currently being translated into several languages).

Below are a list of links to our one-page summary of the latest evidence for the protocol, plus videos of FLCCC Alliance doctors discussing the emerging evidence for the use of ivermectin in the prevention and treatment of COVID-19, and a short list of up-to-date studies and clinical trials on this topic.

Shared from https://covid19criticalcare.com/covid-19-protocols/i-mask-plus-protocol/


Treatment once hospitalized

MATH+ Hospital Treatment Protocol for COVID-19

Below you can download the MATH+ Hospital Treatment Protocol for COVID-19, for use by professionals, with detailed guidance on the timing of initiation along with the suggested initial doses and durations of each component medication. The protocol document is available for download in multiple languages (see below) – more translations are available  here.

Please also review our  I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19, which was developed for the prevention and early outpatient treatment of COVID-19. Both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles. In October 2020, we added ivermectin as a core medication in the prevention and treatment of COVID-19.

Please do not consider these protocols as personal medical advice, but as a recommendation for use by professional providers. Consult with your doctor, share the information on this website and discuss with her/him. Please review our  Disclaimers!

Please check this page regularly for updates – new medications may be added and/or doses changed to existing medications as further scientific studies emerge.

Current MATH+ protocol: version 15, updated on Sept. 18, 2021 (English version, translation updates follow).

Hospital Treat­ment Proto­col for COVID-19

Protocolo de trata­miento hospi­ta­la­rio para COVID-19

Protocolo de tratamento hos­­pi­­­­­ta­­­­­lar para COVID-19

Protocole de traitement hospitalier pour le COVID‐19

Protocollo di trattamento ospedaliero per COVID-19

Protokoll zur Behandlung von COVID-19 im Krankenhaus

For more translations please go to Translations of Selected Files.

переводы · Traducciones · الترجمات · Çeviriler · Traduções · ਅਨੁਵਾਦ · Traduzioni · 翻訳
Tafsiri · Übersetzungen · Översättningar · अनुवाद · Traductions · மொழிபெயர்ப்புகள்
অনুবাদ · Vertalingen · Μεταφράσεις · Tłumaczenia · भाषांतर · Preklady · ترجمہ · అనువాదాలు

About the MATH+ Protocol

Update: On December 14, 2020, the FLCCC Alliance peer-reviewed paper Clinical and Scientific Rationale for the “MATH+” Hospital Treatment Protocol for COVID-19 has been published in the Journal of Intensive Care Medicine. The MATH+ protocol potentially offers a life-saving approach to the management of hospitalized COVID-19 patients. It offers an inexpensive combination of medicines with well-known safety profiles based on strong physiologic rationale and an increasing clinical evidence base.

The MATH+ Hospital Treatment Protocol for COVID-19 is designed for hospitalized patients, to be initiated as soon as possible after they develop respiratory difficulty and require oxygen supplementation. The three core pathophysiologic processes that have been identified are severe hypoxemia, hyperinflammation, and hypercoagulability. This combination medication protocol is designed to counteract these processes either through the use of single agents or in synergistic actions. A unique insight into this disease made by members of our group is that the majority of patients initially present with an inflammatory reaction in the lungs called “organizing pneumonia,” which is the body’s reaction to injury and is profoundly responsive to corticosteroid therapy. If the organizing pneumonia response is left untreated or presents as a rapidly progressive sub-type, a condition called Acute Respiratory Distress Syndrome (ARDS) follows.

The two main therapies that can reverse and/or mitigate the extreme inflammation causing ARDS are the combination of the corticosteroid Methylprednisolone and the antioxidant Ascorbic acid, which is given intravenously and in high doses. Both of these medicines have multiple synergistic physiologic effects and have been shown in multiple randomized controlled trials to improve survival in ARDS, particularly when given early in the disease. Thiamine is given to optimize cellular oxygen utilization and energy consumption, protecting the heart, brain, and immune system. Given the numerous clinical and scientific investigations that have demonstrated consistent, reproducible, and excessive levels of hyper-coagulation, particularly in the severely ill, the anticoagulant Heparin is used to both prevent and help in dissolving blood clots that appear with a very high frequency. The “+” sign indicates several important co-interventions that have a combination of strong physiologic rationale with existing or emerging pre-clinical and clinical data to support their use in similar conditions or in COVID-19 itself, and all with a well-established safety profile. Such adjunctive therapies are continuously being evaluated and amended as the published medical evidence evolves.

Timing is a critical factor in the efficacy of MATH+ and to achieving successful outcomes in patients ill with COVID-19. Patients must go to the hospital as soon as they experience difficulty breathing or have a low oxygen level. The MATH+ protocol should be administered soon after a patient meets criteria for oxygen supplementation (within the first hours after arrival in the hospital), in order to achieve maximal efficacy. Delayed therapy can lead to complications such as the need for mechanical ventilation. If administered early, the MATH+ formula of FDA-approved, safe, inexpensive, and readily available drugs may eliminate the need for ICU beds and mechanical ventilators and return patients to health.

The hospital treatment information shared from
https://covid19criticalcare.com/covid-19-protocols/math-plus-protocol/


I-RECOVER Management Protocol for Long Haul COVID-19 Syndrome (LHCS)

I-RECOVER Management Protocol for Long Haul COVID-19 Syndrome (LHCS)

I-RECOVER Protocol: Version 1, Updated June 16, 2021

The Long Haul COVID-19 Syndrome (LHCS) is an often debilitating syndrome characterized by a multitude of symptoms such as prolonged malaise, headaches, generalized fatigue, sleep difficulties, smell disorder, decreased appetite, painful joints, dyspnea, chest pain and cognitive dysfunction. The incidence of symptoms after COVID-19 varies from as low as 10% to as high as 80%. LHCS is not only seen after the COVID-19 infection but it is being observed in some people that have received vaccines (likely due to monocyte activation by the spike protein from the vaccine). A puzzling feature of the LHCS syndrome is that it is not predicted by initial disease severity; post-COVID-19 frequently affects mild-to-moderate cases and younger adults that did not require respiratory support or intensive care.

The symptom set of LHCS in the majority of cases is very similar to the chronic inflammatory response syndrome (CIRS)/myalgic encephalomyelitis/chronic fatigue syndrome, although in LHCS, symptoms tend to improve slowly in the majority of the cases. Furthermore, the similarity between the mast cell activation syndrome and LHCS has been observed, and many consider post-COVID-19 to be a variant of the mast cell activation syndrome. LHCS is highly heterogenous and likely results from a variety of pathogenetic mechanisms. Furthermore, it is likely that delayed treatment (with ivermectin) in the early symptomatic phase will result in a high viral load, which increases the risk and severity of LHCS.

Although numerous reports describe the epidemiology and clinical features of LHCS, studies evaluating treatment options are glaringly sparse. Indeed, the NICE guideline for managing the long-term effects of COVID-19 provide no specific pharmacologic treatment recommendations.

Given the lack of available treatment recommendations in the setting of large numbers of patients suffering with this disorder globally, the FLCCC developed the I-RECOVER protocol in collaboration with a number of expert clinicians including Dr. Mobeen Syed, Dr. Ram Yogendra, Dr. Bruce Patterson, and Dr. Tina Peers. Although our varied yet often overlapping treatment approaches were initially empiric, while based on both preliminary investigations into and prevailing theoretical pathophysiologic mechanisms of LHCS, the consistently positive clinical responses observed, often profound and sustained, led the collaboration to form the consensus protocol below. As with all FLCCC protocols, we must emphasize that multiple aspects of the protocol may change as scientific data and clinical experience in this condition evolve, thus it is important to check back frequently or join the FLCCC Alliance to receive notification of any protocol changes.

For translations please go to Translations of Selected Files.

переводы · Traducciones · الترجمات · Çeviriler · Traduções · ਅਨੁਵਾਦ · Traduzioni · 翻訳
Tafsiri · Übersetzungen · Översättningar · अनुवाद · Traductions · மொழிபெயர்ப்புகள்
অনুবাদ · Vertalingen · Μεταφράσεις · Tłumaczenia · भाषांतर · Preklady · ترجمہ · అనువాదాలు

i-recover shared from https://covid19criticalcare.com/covid-19-protocols/i-recover-protocol/

By admin